Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagnostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood epa and DHA levels

Abstract

The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, said kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 13 / 584,428, filed Aug. 13, 2012, now U.S. Pat. No. ______, issued ______, which is a continuation-in-part of PCT / US2012 / 025010, filed Feb. 14, 2012, which claims benefit of priority to U.S. Provisional Patent Application Ser. No. 61 / 457,270, filed Feb. 16, 2011, the contents of which are incorporated herein by reference in their entireties.FIELD OF THE INVENTION[0002]The present invention provides a pharmaceutical grade prescription medical food formulation which is used for the dietary management of cardiovascular disease (CVD) patients or any patient who has been found to be deficient in blood omega-3 fatty acids, specifically Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA) and Docosapentaenoic acid (DPA) levels, in combination with a diagnostic assay for determining blood levels of EPA, DPA and DHA.BACKGROUND OF THE INVENTION[0003]In accordance with the findings of...

AI Technical Summary

Benefits of technology

The present invention provides a new composition that can be used to reduce the risk factors associated with cardiovascular disease. The composition contains a specific ratio of EPA to DHA, which is important because EPA is a more potent endothelium-dependent vasorelaxant agonist than DHA. The ratio of EPA to DHA in commercial omega-3 preparations is typically 6:1. The composition can be formulated as an orally administerable unit dosage form and has been shown to be effective in treating various risk factors associated with CVD. The composition can be used to improve heart health and reduce the risk factors associated with cardiovascular disease in humans and animals. The patent also provides a diagnostic assay to monitor the progress of treatment. The composition has a sustained vasodilatory effect, which is beneficial for cardiovascular health.

Problems solved by technology

The prior art fails to teach or suggest the provision of a companion diagnostic assay in conjunction with the formulation.

Images